[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367306-105":59,"doc-detail-367306-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-brca-mutations-age-surgical-indication-and-hormone-status-on-the-molecular-phenotype-of-the-human-fallopian-tube","Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube","","Investigation of the molecular phenotype of the human Fallopian tube (FT) links heterozygous germline BRCA1/2 pathogenic variants to pelvic serous cancer risk, including high-grade serous tubo-ovarian carcinoma. Comprehensive whole-genome bisulfite sequencing, RNA-seq, and proteomic data were generated for over 100 human FT samples with detailed clinical covariates. Findings challenge prior paradigms by showing minimal differences between BRCA1/2 carriers and non-carriers before loss of heterozygosity. Age and surgical indication can confound reported BRCA1/2-associated differences, largely via their effects on cell composition. The study documents variation across normal FT, defining five groups reflecting major cellular and molecular changes across reproductive stages, pregnancy, and aging, and associates gene, protein, and epigenetic alterations with clinical covariates without tying them to heterozygous BRCA1/2 mutation status.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-brca-mutations-age-surgical-indication-and-hormone-status-on-the-molecular-phenotype-of-the-human-fallopian-tube/367306/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-brca-mutations-age-surgical-indication-and-hormone-status-on-the-molecular-phenotype-of-the-human-fallopian-tube/367306.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological role does the human fallopian tube play in pelvic serous cancers?","Question",{"text":112,"@type":113},"The fallopian tube is implicated as a site of origin for pelvic serous cancers, including high-grade serous tubo-ovarian carcinoma. The disease progression is associated with lesions such as STIC in the distal FT.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data types were used to analyze the molecular phenotype of the fallopian tube?",{"text":117,"@type":113},"The study generated whole-genome bisulfite sequencing, RNA-seq, and proteomic data. Samples included extensive clinical covariate annotations.",{"name":119,"@type":110,"acceptedAnswer":120},"Do BRCA1/2 mutation carriers show large molecular differences before loss of heterozygosity?",{"text":121,"@type":113},"No. The results show minimal differences between BRCA1/2 carriers and non-carriers prior to loss of heterozygosity, suggesting earlier paradigms may overstate BRCA-driven alterations at that stage.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367306,1790786284,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Article [https://doi.org/10.1038/s41467-025-58145-2](https://doi.org/10.1038/s41467-025-58145-2)  \nImpact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube  \nReceived: 14 July 2024  \n\n| Accepted: 12 March 2025 |\n| --- |\n| |\n| Check for updates |\n\nIan Beddows 1, Svetlana Djirackor1, Dalia K. Omran 2, Euihye Jung 2, Natalie NC Shih3, Ritu Roy 4, Aaron Hechmer4, Adam Olshen4,5, Guillaume Adelmant 6,7,8, Ann Tom6,7,8, Jacob Morrison1, Marie Adams 9,  \nDaniel C. Rohrer 10, Lauren E. Schwartz3, Celeste Leigh Pearce11, Heidi Auman12, Jarrod A. Marto 6,7,8, Charles W. Drescher13,14 , Ronny Drapkin 2,15  & Hui Shen 1   \nThe human Fallopian tube (FT) is an important organ in the female reproductive system and has been implicated as a site of origin for pelvic serous cancers, including high-grade serous tubo-ovarian carcinoma(HGSC). We have generated comprehensive whole-genome bisulﬁte sequencing, RNA-seq, and proteomic data of over 100 human FTs, with detailed clinical covariate annotations. Our results challenge existing paradigms that extensive epigenetic, transcriptomic and proteomic alterations exist in the FTs from women carrying heterozygous germline BRCA1/2pathogenic variants. Weﬁnd minimal differences between BRCA1/2 carriers and non-carriers prior to loss of heterozygosity. Covariates such as age and surgical indication can confound BRCA1/2-related differences reported in the literature, mainly through their impact on cell composition. We systematically document and highlight the degree of variations across normal human FT, deﬁning ﬁve groups capturing major cellular and molecular changes across various reproductive stages, pregnancy, and aging. We are able to associate gene, protein, and epigenetic changes with these and other clinical covariates, but not heterozygous BRCA1/  \n2 mutation status. This sheds new light into prevention and early detection of tumorigenesis in populations at high-risk for ovarian cancer.  \nThe human Fallopian tube (FT), also known as the uterine tube or oviduct, plays a crucial role in female reproductive biology. It is a highly specialized organ for transporting the ovum and is the site for fertilization and early development. It is now clear that the FT is a site of origin for pelvic serous cancer, a spectrum of diseases that includes high-grade serous cancer of the ovary, FT, and peritoneum1–6. A widely accepted tumorigenesis model includes stepwise progression starting  \nwith clonal expansion of histologically normal, lowly proliferativep53-mutated, secretory epithelial cells. This is followed by progressive accumulation of additional molecular alterations, increased cellular proliferation, and cytologic atypia ultimately leading to a serous tubalintraepithelial cancer (STIC), localized almost exclusively in the ﬁmbria of the distal FT. Invasive serous cancer arises directly from STIC cells within the FT or in the ovary/peritoneal cavity as a consequence of  \nA full list of afﬁliations appears at the end of the paper. e-mail: [cdresche@fredhutch.org](cdresche@fredhutch.org); [rdrapkin@pennmedicine.upenn.edu](rdrapkin@pennmedicine.upenn.edu); [hui.shen@vai.org](hui.shen@vai.org)  \nexfoliation of STIC cells from the lumen of the FT7–11. Phylogenetic analyses suggest the entire process spans decades with p53 signatures arising 20 or more years before serous cancer diagnosis and STIC lesions and early invasive cancer developing roughly 6.5 years and 2 years before diagnosis respectively9,11.  \nBRCA1 and BRCA2 mutation carriers (hereafter BRCAm) are at signiﬁcantly elevated risk for serous ovarian cancer with a lifetime risk of ~15–40%, depending on the speciﬁc mutation, relative to those without pathogenic mutations (hereafter non-BRCAm). An estimated 30% of serous cancers have BRCA1/2 functional loss12,13. Risk increases with age and is reduced by breastfeeding, oral contraceptive pill use, and prior tubal ligation14. It is well e","cbCaifyQsiruaTNI","https://ap.wps.com/l/cbCaifyQsiruaTNI","pdf",8356476,17,"English","# Background and rationale\n## Role of the fallopian tube in pelvic serous cancer\n## BRCA1/2 risk and clinical context\n## Knowledge gaps in molecular mechanisms\n# Study approach and key findings\n## Multi-omics profiling across human FT samples\n## Impact of BRCA status versus covariates\n## Variation across reproductive stages, pregnancy, and aging","[{\"question\":\"What biological role does the human fallopian tube play in pelvic serous cancers?\",\"answer\":\"The fallopian tube is implicated as a site of origin for pelvic serous cancers, including high-grade serous tubo-ovarian carcinoma. The disease progression is associated with lesions such as STIC in the distal FT.\"},{\"question\":\"What data types were used to analyze the molecular phenotype of the fallopian tube?\",\"answer\":\"The study generated whole-genome bisulfite sequencing, RNA-seq, and proteomic data. Samples included extensive clinical covariate annotations.\"},{\"question\":\"Do BRCA1/2 mutation carriers show large molecular differences before loss of heterozygosity?\",\"answer\":\"No. The results show minimal differences between BRCA1/2 carriers and non-carriers prior to loss of heterozygosity, suggesting earlier paradigms may overstate BRCA-driven alterations at that stage.\"}]","Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube | PDF",1790170173,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/341d3bccda7ea4ff633ac0c2fe3a9256.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef353e9e312a6b25299d9b68fc226067.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b2ff91231b6a860615b22ff33b506d2.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ab3b6ddf5a6b7e9a47526988f329160.webp",980,1301]